U.S. Auto Stock News

Innoviva (INVA) just cleared a major hurdle with FDA approval for NUZOLVENCE, a first in class single dose oral antibiotic for uncomplicated gonorrhea, potentially reshaping both its pipeline value and long term growth story. See our latest analysis for Innoviva. The NUZOLVENCE approval lands at a time when Innoviva’s share price has climbed 13.62 percent year to date and 6.46 percent over 90 days, while its 3 year total shareholder return of 51.73 percent signals momentum that investors...

Wondering if WillScot Holdings is quietly turning into a value story after a rough stretch? This breakdown will help you figure out whether the current share price really reflects its long term potential. The stock has inched up about 1.9% over the last week and 10.0% over the past month, even though it is still down roughly 41.4% year to date and 41.6% over the last year. This hints that sentiment might be starting to shift. Recent coverage has focused on how WillScot is repositioning...

In recent days, Arbor Realty Trust has drawn heightened attention as multiple research firms lowered their recommendations, reflecting growing caution around its outlook and earnings estimates. This shift in analyst sentiment, combined with concerns highlighted by earnings forecast revisions, has sharpened the market’s focus on whether Arbor’s current valuation reflects its risks and potential. We’ll now examine how this recent wave of analyst downgrades could reshape Arbor Realty Trust’s...

W. P. Carey Inc. recently increased its quarterly cash dividend to $0.920 per share (US$3.68 annualized) and announced the upcoming departure of long-serving director Mark A. Alexander for health reasons, while also expanding its commercial real estate portfolio with the acquisition of a Life Time health club in Dublin, Ohio. Together, the dividend increase and ongoing property acquisitions highlight management’s current emphasis on sustaining shareholder income while continuing to grow...

SLB (SLB) just landed a five year contract with Aramco to deliver advanced stimulation, well intervention, frac automation, and digital solutions across Saudi Arabia’s unconventional gas fields, deepening its role in the Kingdom’s gas expansion plans. See our latest analysis for SLB. The Aramco win caps a busy stretch for SLB, coming shortly after its digital collaboration with Shell and an ESOP related share offering. It seems to be nudging sentiment back onside, even though the 1 year total...

Many investors are asking whether Allstate at around $209 a share is still a smart buy or if most of the upside is already priced in. This article unpacks that question in detail. Despite a relatively flat 7 day move and a modest 1.6% dip over the last month, Allstate is still up 8.9% year to date and 118.6% over 5 years. This indicates that long term holders have been rewarded even if short term action looks quieter. Recently, the stock has been in focus as investors reassess large US...

Flex (FLEX) has quietly turned into one of the market’s steadier compounders, with the stock up roughly 64% this year and about 3x over the past 3 years. See our latest analysis for Flex. The stock’s 30 day share price return of 11.59 percent on a last close of 63.55 dollars builds on strong year to date momentum. Flex’s three year total shareholder return above 300 percent shows this has been a sustained, rerating story rather than a quick trade. Given that kind of run, it can be worth...

BioCryst Pharmaceuticals previously announced that the FDA approved its New Drug Application for an oral pellet formulation of once-daily ORLADEYO (berotralstat) as the first targeted oral prophylactic therapy for hereditary angioedema in children aged 2 to under 12 years in the U.S. This pediatric-friendly oral option addresses a long-standing gap where younger hereditary angioedema patients relied solely on intravenous or subcutaneous treatments, potentially easing daily treatment burden...

Republic Services (RSG) has been treading water lately, with the stock roughly flat over the past month and down about 6% in the past 3 months, despite steady earnings growth. See our latest analysis for Republic Services. Over the past year, Republic Services has quietly delivered a mid single digit total shareholder return while its 3 year and 5 year total shareholder returns of roughly 71% and 138% suggest longer term momentum remains firmly intact, even as near term share price returns...

Performance Food Group has announced a leadership succession in which long-time Chairman and CEO George Holm will step down as CEO to become Executive Chair, while current President and COO Scott McPherson will take over as CEO and join the board, with the transition effective January 1, 2026. This handover elevates an executive with deep experience across Performance Food Group’s core segments and prior CEO credentials, while keeping Holm closely involved in acquisitions and overall...

Peabody Energy has outlined a long-term leadership transition, keeping President and CEO James C. Grech in place until May 15, 2028, before moving him into an advisory role through 2030 as the board conducts an active search for his successor. This extended handover, pairing continuity in the C-suite with a clear succession framework, gives investors unusual visibility into Peabody’s governance and planning horizon. With a defined CEO transition stretching to 2028, we’ll now examine how this...

In December 2025, Google Cloud and Palo Alto Networks expanded their partnership to integrate Prisma AIRS across Google’s AI services, including Vertex AI and Agent Engine, and entered a new multibillion-dollar agreement to migrate Palo Alto’s internal security platforms onto Google Cloud’s infrastructure. This deeper alignment aims to build security into every layer of hybrid multicloud AI development, positioning Palo Alto Networks as a core provider of end-to-end protection for...

Nutanix (NTNX) has quietly slipped over the past month, even as its longer term three year return still looks strong. With shares now well below recent highs, investors are rechecking the growth story. See our latest analysis for Nutanix. Over the past year, Nutanix has shifted from a hot momentum story to a consolidation phase, with a 1 year total shareholder return of minus 19 percent. At the same time, the 3 year total shareholder return of just over 100 percent still reflects a strong...

Fidelity National Information Services has agreed to pay US$210 million to settle a long‑running investor lawsuit over alleged misstatements tied to its 2019 Worldpay acquisition, with the deal pending court approval and no admission of wrongdoing. The settlement caps years of Worldpay-related controversy following leadership changes and the sale of a majority stake in the business in 2023, potentially clearing a governance overhang as new investigations into board conduct emerge. With FIS...

On December 11, 2025, Abercrombie & Fitch promoted Robert J. Ball from Senior Vice President and Chief Financial Officer to Executive Vice President and Chief Financial Officer, alongside raising its annual profit forecast after strong third-quarter results driven by resilient demand, particularly at Hollister. This combination of upgraded guidance, leadership continuity in the finance function, and momentum at Hollister underscores how operational execution and governance decisions are...

If you are wondering whether Vistra is still a smart buy after its huge multi‑year run, or if most of the upside is already priced in, this breakdown can help you think through whether the current share price stacks up against its fundamentals. The stock has cooled off recently, slipping about 7.5% over the past month, even as it is still up 8.2% year to date and an eye‑catching 614.9% over 3 years and 824.0% over 5 years. This pattern hints at strong long‑term optimism alongside shifting...

In recent months, Novavax has been shifting from direct commercial vaccine sales toward a royalty- and milestone-focused partnership model with Sanofi, while contending with tighter FDA vaccine standards and a smaller COVID booster market. At the same time, activist investor Shah Capital, which owns about 8.3% of Novavax, has publicly urged the board to pursue a sale, arguing the company’s value could be far above its roughly US$1.10 billion market capitalization. We’ll now explore how Shah...

Earlier this week, Novanta reported a 1.4% year-on-year revenue increase that came in 0.8% above analyst expectations, but EBITDA fell well short of forecasts and marked the slowest revenue growth across its electronic components peers. This mix of stronger-than-expected sales and weaker profitability raises questions about the efficiency of Novanta’s growth engine at a time when peers appear to be scaling more effectively. We’ll now examine how this revenue beat but EBITDA miss may...

Wondering if Bausch + Lomb at around $17 a share is a hidden bargain or a value trap? This article will walk through the numbers in plain English so you can decide for yourself. The stock has inched up 0.8% over the last week and 10.1% across the past month, even though it is still down 5.5% year to date and 4.8% over the last year. This hints that sentiment might be shifting after a tougher stretch. Recent headlines have focused on Bausch + Lomb expanding its eye health portfolio and...

If you are wondering whether American Express is still attractive after such a strong run, or if you might be late to the party, this section will walk through what the market is really pricing in. The stock has climbed 2.0% over the last week, 7.6% over the past month, and is up 28.4% year to date, building on gains of 27.6% over 1 year, 176.1% over 3 years, and 241.2% over 5 years. Recent headlines have focused on American Express cementing its premium cardholder base and expanding co...

Wondering if Goldman Sachs Group at around $910 a share is still a smart buy, or if the best gains are already in the rear view mirror? This breakdown will help you decide whether the current price still stacks up against its fundamentals. The stock has climbed 4.4% over the last week, 15.2% over the past month and 58.4% year to date, adding to a 59.5% 1 year return and a 295.3% gain over five years that naturally raises questions about how much value is left. Recently, markets have been...

If you are wondering whether Enterprise Products Partners is still a buy at around $32 a unit, you are not alone. Income focused investors have been debating if its current price really reflects the quality of its cash flows. The unit price has been fairly steady recently, up 0.2% over the last week and about 1.0% year to date, but that sits on top of longer term gains of 67.5% over three years and 137.5% over five years that have reset expectations. Those returns come as Enterprise...

Yalla Group (NYSE:YALA) just caught fresh attention after management bought back 1.49 million shares for about $10.9 million, reflecting a five year stretch of roughly 34% annual earnings growth. See our latest analysis for Yalla Group. Those buybacks come after a powerful run, with the share price now at $7.16 and a strong year to date share price return helping underpin a robust three year total shareholder return. This suggests positive momentum rather than a fading story. If Yalla's...

If you have been wondering whether Energy Transfer is still a value play or if most of the easy money has already been made, you are not alone. This article is going to walk through that question step by step. Despite being down 16.8% year to date and about 10.0% over the last year, the stock is still sitting on gains of roughly 80.3% over 3 years and nearly 295.9% over 5 years. This suggests that the market has already reassessed this name more than once. Recent moves have been shaped by a...